PRIMA-1MET, which restores mutant p53 activity (R273H and R175H) by converting mutant p53 to a stable and active form that induces apoptosis in cancer cells, has successfully completed a Phase I clinical trial [98‒100] . Here, TP53 is linked to cancer.